Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%

Written by Emily J. Thompson, Senior Investment Analyst

VNDA-3.25%

AEHL+4.51%

AFJK-18.7%

Source: Benzinga

Updated: Dec 31 2025

0mins

Source: Benzinga

FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.

VNDA

$7.45+Infinity%1D

Analyst Views on VNDA

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 7.700

Low

11.00

Averages

15.50

High

20.00

Current: 7.700

Low

11.00

Averages

15.50

High

20.00

H.C. Wainwright

maintain

$22

Al Analysis

2026-01-08

Reason

H.C. Wainwright

Price Target

$22

Al Analysis

2026-01-08

maintain

Reason

H.C. Wainwright notes that Vanda Pharmaceuticals announced that it has received a decision letter from the FDA's Center for Drug Evaluation and Research concluding that the supplemental New Drug Application for HETLIOZ - tasimelteon - for the treatment of jet lag disorder cannot be approved in its current form. In the firm's view, the rejection of tasimelteon constitutes only a minor setback and may not mark the end of dialogue over the compound in this indication. Furthermore, Wainwright draws investors' attention to the fact that its valuation assessment did not include any contribution from sales of tasimelteon in treatment of jet lag. Accordingly, the firm reiterates a Buy rating and a price target of $22 on the shares.

H.C. Wainwright

Buy

maintain

$20 -> $22

2026-01-05

Reason

H.C. Wainwright

Price Target

$20 -> $22

2026-01-05

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Vanda Pharmaceuticals to $22 from $20 and keeps a Buy rating on the shares. The firm cites the addition of tradipitant sales into the model following the approval for the treatment of motion sickness for the target boost.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNDA

Unlock Now

Cantor Fitzgerald

Olivia Brayer

Overweight

maintain

$11

2025-12-31

Reason

Cantor Fitzgerald

Olivia Brayer

Price Target

$11

2025-12-31

maintain

Overweight

Reason

Cantor Fitzgerald analyst Olivia Brayer keeps an Overweight rating on Vanda Pharmaceuticals with an $11 price target after the FDA approved Nereus for the prevention of motion sickness. The motion sickness opportunity could add upside to estimates, but the bigger implication is that the approval could have an "important look-through" for Vanda's GLP-1 nausea program, which begins Phase 3 in 2026, the analyst tells investors in a research note. Cantor views Nereus' label as "fairly broad." Vanda has talked about motion sickness as a several hundred million peak sales opportunity, the firm adds.

B. Riley

Buy

maintain

$11 -> $14

2025-12-31

Reason

B. Riley

Price Target

$11 -> $14

2025-12-31

maintain

Buy

Reason

B. Riley raised the firm's price target on Vanda Pharmaceuticals to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion sickness. The news supports the view that Vanda is an "ongoing turnaround story" trading at an "excessive discount" heading into two more potential approvals within the next 12 months, the analyst tells investors in a research note. Riley says that while the approval could unlock over $100M in peak revenue, the greater significance is in the implications for tradipitant approval in GLP-1 related nausea.

About VNDA

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.